Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20103301 | 0.78 | FFAR4 (0.37) | FFAR4FFAR1CCNT1CDK9EGLN1 | |
| SCHEMBL20103308 | 0.77 | CCNT1 (0.42) | TLR9TLR8TLR7FFAR4FFAR1 | |
| SCHEMBL21688373 | 0.69 | CDK9 (0.56) | FFAR4FFAR1CCNT1CDK9 | |
| SCHEMBL20103303 | 0.68 | CDK9 (0.47) | FFAR4FFAR1CCNT1CDK9 | |
| SCHEMBL20103605 | 0.68 | FFAR1 (0.40) | TLR9TLR8TLR7FFAR4FFAR1 | |
| SCHEMBL3313569 | 0.64 | NNMT (0.39) | FFAR4AAK1 | |
| SCHEMBL19179872 | 0.63 | FFAR1 (0.38) | FFAR1AAK1BACE1 | |
| SCHEMBL20103177 | 0.62 | FFAR1 (0.43) | TLR9TLR8TLR7FFAR4FFAR1 | |
| SCHEMBL21644913 | 0.62 | FFAR1 (0.43) | TLR9TLR8TLR7FFAR4FFAR1 | |
| SCHEMBL20103176 | 0.62 | FFAR1 (0.43) | TLR9TLR8TLR7FFAR4FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | TLR9 709/4885TLR8 726/4885TLR7 412/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | TLR9 709/4885TLR8 726/4885TLR7 412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.